ArticleBioprocess and biosystems engineering2025
Degradation and transformation of tylvalosin by newly selected Providencia vermicola strain CT1: removal efficiency, pathways, mechanisms, and actual applications.
Article in Bioprocess and biosystems engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Eco-efficient Pseudomonas-Rhodococcus combination technique to boost the BTEX degradation.Archives of microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Tylvalosin (TAT) is a widely used veterinary antibiotic whose residual contaminants promote antibiotic resistance and pose potential risks to human health and ecosystems. This study successfully isolated and identified a TAT-degrading bacterial strain, Providencia vermicola strain CT1, through 16S rRNA analysis and biochemical tests. Under optimized conditions (30 °C, pH = 6, initial TAT concentration of 300 mg/L, and bacterial culture volume of 50 mL), strain CT1 achieved a TAT degradation percentage of 97.1%. The degradation process followed a first-order kinetic model and was primarily driven by extracellular metabolites. GC-MS analysis identified that strain CT1 degrades TAT to produce small molecules such as 3-methylbutanoic acid, ethyl acetate, and 3-iminopentan-2-one. Strain CT1 effectively degraded TAT in actual wastewater samples, achieving 95% degradation within 60 h, and significantly reduced the COD, BOD₅, and NH₄⁺-N concentrations. These findings provide theoretical guidelines for removing TAT and other macrolide antibiotic contaminants from the environment.
Indexed as
Identifiers
40074936What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.